

ASX RELEASE

10 July 2018

## **KAZIA SHAREHOLDER INFORMATION SESSIONS - UPDATE**

Sydney, 10 July 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, thanks investors for registering for our upcoming shareholder information sessions in Melbourne and Sydney. We have been experiencing technical difficulties with our website and to ensure all RSVPs are noted, **request that shareholders reconfirm their RSVP.**

**To do so, please RE-REGISTER FOR THE SESSION OF YOUR CHOICE via email to [info@kaziatherapeutics.com](mailto:info@kaziatherapeutics.com) indicating:**

- Your name
- Email address
- Contact telephone number
- Whether you will be attending in Melbourne or Sydney; and
- How many people will be in attendance with you

Please kindly register your interest by COB Wednesday 11 July 2018.

### **Shareholder briefing sessions - details:**

<b>Melbourne</b>	Monday 16 July, 5:30 – 7:30 pm Baker McKenzie offices Level 19, 181 William Street Melbourne
<b>Sydney</b>	Wednesday 18 July, 5:30 – 7:30 pm Baker McKenzie offices, Tower 1, level 46, 100 Barangaroo Avenue Sydney

### **Briefing webcast and Q+A session:**

For those shareholders unable to attend the briefing sessions in person, Kazia will make available the webcast of the Sydney shareholder briefing session within a few days of the event.

[ENDS]

### **Board of Directors**

**Mr Iain Ross** Chairman, Non-Executive Director

**Mr Bryce Carmine** Non-Executive Director

**Mr Steven Coffey** Non-Executive Director

**Dr James Garner** Chief Executive Officer, Managing Director

**Media and investor relations**

Glen Zurcher

E: [glen.zurcher@irdepartment.com.au](mailto:glen.zurcher@irdepartment.com.au)

T: +61 420 249 299

**About Kazia Therapeutics Limited**

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing.

For more information, please visit [www.kaziatherapeutics.com](http://www.kaziatherapeutics.com).